Biosimilar Samfenet wins patent invalidation against Herceptin in Korea - (The Korea Herald via NewsPoints Desk)

  • According to industry sources, Samsung Bioepis' breast cancer treatment biosimilar Samfenet, known as Ontruzant outside Korea, won a patent invalidation suit against the original Roche drug Herceptin, reported The Korea Herald.

  • Last week, Korea's Intellectual Property Trial and Appeal Board accepted Samsung Bioepis' claim that Roche's patent, which was set to expire in May, lacks patentability.

  • Samsung Bioepis gained Korean regulatory approval in 2017 for Samfenet, which has been distributed domestically by Daewoong Pharmaceutical since March 2018.

  • Herceptin records annual sales of 80 billion won in Korea and 8 trillion won globally, the news source said.  

  • Celltrion, which produces a Herceptin biosimilar called Herzuma, invalidated another of the patents for Roche's drug in 2015.

  • Herzuma, which gained Korean approval in 2014, recorded 7.7 billion won in sales last year, according to the news source.

To read more NewsPoints articles, click here.